Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Infectious disease R&D Pipeline

Antiviral, antibacterial, and infectious disease vaccine pipeline programs.

Programs 1,112

Quick answer

Infectious disease: NovaPharmaNews indexes 1,112 infectious disease clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Antiviral, antibacterial, and infectious disease vaccine pipeline programs.

Top sponsors

Pipeline programs

Page 15 of 24

  1. 222110

    GlaxoSmithKline

    Hepatitis B, Chronic

    phase 1 other active

    1 trial

  2. 222261

    GlaxoSmithKline

    Respiratory Syncytial Virus Infections

    phase 1 other active

    1 trial

  3. 22265

    Bayer AG

    Coagulopathy, Sepsis

    phase 1 other active

    1 trial

  4. 222778

    GlaxoSmithKline

    Urinary Tract Infections

    phase 1 other active

    1 trial

  5. 22534

    Bayer AG

    Onchocerciasis (river blindness): is an infectious disease caused by Onchocerca volvulus, a parasitic nematode worm. The disease is contracted through the bite of an infected blackfly of the genus Simulium, which transmits third-stage infective larvae. An estimated 18 million people suffer from onchocerciasis, with 99% cases in 31 African countries, and 187 million people at risk Onchocercal dermatitis is the most common symptom of the disease, but severe visual impairment and blindness are the most severe complication, and onchocerciasis is the world’s second-leading infectious cause of blindness. Programs for the treatment and control of onchocerciasis through mass drug administration of ivermectin have been in place for over 20 years. However, they require patients to be given treatment (ivermectin) at regular intervals for the life of the adult worm (up to 15 years), making implementation extremely difficult in endemic countries. Emodepside is a registered drug for animal health, marketed by Bayer Animal Health GmbH under the name of Profender® (in combination with praziquantel) or Procox® (in combination with toltrazuril). It is a cyclooctadepsipeptide anthelmintic drug., Soil-transmitted helminth infection: Soil-transmitted helminthiasis is caused by one of the three soil-transmitted helminths (STH), Ascaris lumbricoides, Trichuris trichiura and hookworm (Ancylostoma duodenale and Necator americanus). Currently, STH still infects about 1.5 billion people worldwide, mostly in tropical and subtropical regions. Emodepside is a registered drug for animal health, marketed by Bayer Animal Health GmbH under the name of Profender® (in combination with praziquantel) or Procox® (in combination with toltrazuril). It is a cyclooctadepsipeptide anthelmintic drug.

    phase 1 other active

    1 trial

  6. 22537

    Bayer AG

    Soil-transmitted helminth infection, Onchocerciasis (river blindness)

    phase 1 other active

    1 trial

  7. 480 mg Piperaquine phosphate

    CNS Pharmaceuticals

    Malaria

    phase 1 small molecule completed

    1 trial

  8. 9vHPV Vaccine plus BCG Vaccine Mix for percutaneous use

    Lxo Ireland Designated Activity Company

    HPV Infection

    phase 1 mab active

    1 trial

  9. A clinical study of MK-1289 in healthy adult men (MK-1289-001)

    Merck Sharp and Dohme

    COVID-19 Infection

    phase 1 other active

    1 trial

  10. A clinical study of MK-3508 in healthy people (MK-3508-006)

    Merck Sharp and Dohme

    Respiratory syncytial virus infection

    phase 1 other active

    1 trial

  11. A clinical study of MK-4646 in healthy people (MK-4646-002)

    Merck Sharp and Dohme

    HIV infection

    phase 1 other active

    1 trial

  12. A clinical study of MK-4646 in people with HIV (MK-4646-003)

    Merck Sharp and Dohme

    HIV infection

    phase 1 other active

    1 trial

  13. A single-dose for infection

    Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.

    infection

    phase 1 other active

    1 trial

  14. A single-dose for infections

    Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.

    infections

    phase 1 other active

    1 trial

  15. A study to compare two different aramchol formulations in healthy volunteers.

    Galmed Pharmaceuticals

    Nonalcoholic fatty liver disease, Nonalcoholic steatohepatitis, Primary sclerosing cholangitis

    phase 1 other active

    1 trial

  16. AB-101

    Arbutus Biopharma Corp

    Chronic Hepatitis b

    phase 1 small molecule completed

    1 trial

  17. AB-101-001

    Arbutus Biopharma Corp

    Chronic hepatitis B virus Infection

    phase 1 other active

    1 trial

  18. AB-836

    Arbutus Biopharma Corp

    Chronic Hepatitis

    phase 1 small molecule terminated

    1 trial

  19. ABI-4334

    ASSEMBLY BIOSCIENCES, INC.

    Chronic Hepatitis B

    phase 1 small molecule completed

    1 trial

  20. ABI-4334 Tablet

    ASSEMBLY BIOSCIENCES, INC.

    Chronic Hepatitis B

    phase 1 small molecule completed

    1 trial

  21. ABI-4334-102

    ASSEMBLY BIOSCIENCES, INC.

    chronic hepatitis B virus infection (cHBV)

    phase 1 other active

    1 trial

  22. ABI-6250

    ASSEMBLY BIOSCIENCES, INC.

    Hepatitis Delta Virus

    phase 1 small molecule completed

    1 trial

  23. ABI-H2158

    ASSEMBLY BIOSCIENCES, INC.

    Chronic Hepatitis B

    phase 1 small molecule completed

    3 trials

  24. ABI-H2158 Reference Formulation

    ASSEMBLY BIOSCIENCES, INC.

    Chronic Hepatitis B

    phase 1 small molecule completed

    1 trial

  25. ABI-H3733

    ASSEMBLY BIOSCIENCES, INC.

    Chronic Hepatitis B

    phase 1 small molecule completed

    1 trial

  26. ABI-H3733 Liquid Oral Dosage Form

    ASSEMBLY BIOSCIENCES, INC.

    Chronic Hepatitis B

    phase 1 small molecule completed

    1 trial

  27. ALG-000184

    Aligos Therapeutics

    Chronic Hepatitis B

    phase 1 small molecule completed

    1 trial

  28. ALG-010133

    Aligos Therapeutics

    Chronic Hepatitis B

    phase 1 small molecule terminated

    1 trial

  29. ALG-020572

    Aligos Therapeutics

    Chronic Hepatitis B

    phase 1 small molecule terminated

    1 trial

  30. ALG-055009

    Aligos Therapeutics

    NASH - Nonalcoholic Steatohepatitis

    phase 1 small molecule completed

    1 trial

  31. ALG-097558

    Aligos Therapeutics

    COVID-19

    phase 1 small molecule completed

    3 trials

  32. ALG-125755

    Aligos Therapeutics

    Chronic Hepatitis B

    phase 1 small molecule terminated

    1 trial

  33. ALN-HBV

    Alnylam Netherlands B.V.

    Hepatitis B

    phase 1 small molecule terminated

    1 trial

  34. ALN-HSD

    Alnylam Netherlands B.V.

    Nonalcoholic Steatohepatitis

    phase 1 small molecule terminated

    1 trial

  35. ALS-002158

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C, Chronic

    phase 1 small molecule terminated

    1 trial

  36. ALS-002200

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C, Chronic

    phase 1 small molecule completed

    1 trial

  37. APC148-001

    Lacuna Pharma Pty Ltd

    Urinary tract infections (UTIs)/complicated UTI (cUTI)

    phase 1 other active

    1 trial

  38. APR002

    BRIGHT MINDS BIOSCIENCES INC.

    COVID-19

    phase 1 small molecule completed

    1 trial

  39. ARC-521 Injection

    Arrowhead Pharmaceuticals Ireland Limited

    Hepatitis B

    phase 1 small molecule terminated

    1 trial

  40. ARS-1 with URTI

    Ars Pharmaceuticals Irl Limited

    Upper Respiratory Tract Infection

    phase 1 small molecule completed

    1 trial

  41. AT-527

    Atea Pharmaceuticals

    Chronic Hepatitis C

    phase 1 small molecule completed

    1 trial

  42. Active Delta-9-THC

    BRIGHT MINDS BIOSCIENCES INC.

    HIV Infections

    phase 1 small molecule completed

    1 trial

  43. Administration of the malaria inoculum

    CNS Pharmaceuticals

    Malaria

    phase 1 mab completed

    1 trial

  44. Alirocumab

    Regeneron UK Limited

    Sepsis

    phase 1 small molecule completed

    1 trial

  45. Antibody UB-421

    United Therapeutics Europe Ltd

    HIV-1 Infection in Adults (Asymptomatic)

    phase 1 small molecule completed

    1 trial

  46. Artesunate (Test)

    Pfizer

    Falciparum Malaria

    phase 1 small molecule completed

    1 trial

  47. Azithromycin Pill

    Arrowhead Pharmaceuticals Ireland Limited

    Infections

    phase 1 small molecule active

    1 trial

  48. B/F/TAF

    Gilead Sciences Ireland UC

    HIV-1-infection

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many infectious disease pipeline programs are tracked?

1,112 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.